



Form PTO-1449 (modified)

Atty. Docket No.
UTSC:755USSerial No.
10/618,102Applicant
Edward H. Lin *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
July 11, 2003Group:
1623-1637

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
TS	A1	6,329,179	12/11/01	Kopreski	435	91.2	3/14/97
TS	A2	6,037,129	3/14/00	Cole <i>et al.</i>	435	6	5/28/98

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
TS	C1	Asahara <i>et al.</i> , "VEGF contributes to postnasal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells," <i>EMBO J.</i> , 18(14):3964-3972, 1999.
	C2	Bhatia, "AC133 expression in human stem cells," <i>Leukemia</i> , 15(11):, 1685-1688, 2001.
	C3	Boyer <i>et al.</i> , "Isolation of endothelial cells and their progenitor cells from human peripheral blood," <i>J. Vasc. Surg.</i> , 31(1-1):181-189, 2000.
	C4	Buhring <i>et al.</i> , "AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors," <i>Blood</i> , 94(2):832-833, 1999.
	C5	Byrne and Bundred, "Surrogate markers of tumoral angiogenesis," <i>Biological Markers</i> , 15(4):334-339, 2000.
	C6	Corbeil <i>et al.</i> , "The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions," <i>Journal of Biological Chemistry</i> , 275(8):5512-5520, 2000.
TS	C7	Dimitriou <i>et al.</i> , "In vitro proliferative and differentiating characteristics of CD133(+) and CD34(+) cord blood cells in the presence of thrombopoietin (TPO) or erythropoietin (EPO): potential implications for hematopoietic cell transplantation," <i>Leukemia Research</i> , 27(12):1143-1151, 2003.

25330684.1


EXAMINER:

Teresa Strelcleg

DATE CONSIDERED:

4/7/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. UTSC:755US	Serial N . 10/618,102
Applicant Edward H. Lin et al.			
Filing Date: July 11, 2003		Group: 1623-1637	
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
TS ✓	C8	Folkman et al., "Angiogenesis research: guidelines for translation to clinical application," <i>Thrombosis Haemostasis</i> , 86:23-33, 2001.
✓	C9	Forraz et al., "AC133+ umbilical cord blood progenitor demonstrate rapid self-renewal and low apoptosis," <i>British Journal of Haematology</i> , 119(2):516-524, 2002.
✓	C10	Gill et al., "Vascular trama induces rapid but transient mobilization of VEGFR2+AC133+ Endothelial precursor cells," <i>Circ. Res.</i> , 88(2):167-174, 2001.
✓	C11	Handgretinger et al., "Biology and plasticity of CD133+ hematopoietic stem cells," <i>Annals of the New York Academy of Sciences</i> , 996:141-151, 2003.
✓	C12	Hariharan et al., "Human immunodeficiency virus infection of human placental cord blood CD34+AC133+ stem cells and their progeny," <i>AIDS Res. Hum. Retroviruses</i> , 15(17):1545-1552, 1999.
✓	C13	Hurvitz et al., "Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer(CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as a first-line therapy in subjects with metastatic CRC," PRO ASCO Conference, Chicago, Ill., abst #3536, 2003.
✓	C14	Kanayasu-Toyoda et al., "CD31 (PECAM-1)-bright cells derived from AC133-positive cells in human peripheral blood as endothelial-precursor cells," <i>Journal of Cellular Physiology</i> , 195(1):119-129, 2003.
✓	C15	Lee et al., AC133 antigen as a prognostic factor in acute leukemia," <i>Leukemia Research</i> , 25(9):757-767, 2001.
✓	C16	Marchetti et al., "Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation," <i>Lab. Invest.</i> , 82(6), 2002.
✓	C17	Miraglia et al., "A response to AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family?" <i>Blood</i> , 91(11):4390-4391, 1998.
✓	C18	Mundhenke et al., "Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin," <i>Clinical Cancer Res.</i> , 7:3366-3374, 2001.
TS ✓	C19	Nakatani et al., "Circulating endothelial cells in Kawasaki disease," <i>Clinical & Experimental Immunology</i> , 131(3):536-540, 2003.

25330684.1

EXAMINER: *Teresa Stuelecia*

DATE CONSIDERED: 4/7/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

DEC 19 2003

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSC:755US

Serial No.

10/618,102

Applicant

Edward H. Lin *et al.*

Filing Date:

July 11, 2003

Group:

1623 1637

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
T5 ✓	C20	Reyes <i>et al.</i> , "Origin of endothelial progenitors in human postnatal bone marrow," <i>J. Clin. Invest.</i> , 109(3):337-346, 2002.
✓	C21	Reyes <i>et al.</i> , "Purification and ex vivo expansion of postnasal human marrow mesodermal progenitor cells," <i>Blood</i> , 98(9):2615-2625, 2001.
✓	C22	Salven <i>et al.</i> , "VEGFR-3 and CD 133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells," <i>Blood</i> , 101(1):168-172, 2003.
✓	C23	Schmeisser <i>et al.</i> , "Monocytes coexpress endothelial and macrophagocytic linkage markers and form cord-like structures in Matrigel under angiogenic conditions," <i>Cardiovascular Res.</i> , 49:671-680, 2001.
✓	C24	Shi <i>et al.</i> , "Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis," <i>Cancer Res.</i> , 60:2579-2583, 2000.
✓	C25	Shi <i>et al.</i> , "Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells," <i>Oncogene</i> , 20:3751-3761, 2001.
✓	C26	Singh <i>et al.</i> , "Identification of a cancer stem cell in human brain tumors," <i>Cancer Res.</i> , 63:5821-5828, 2003.
✓	C27	Ueda <i>et al.</i> , "DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome," <i>British Journal of Haematology</i> , 123(2):288-296, 2003.
✓	C28	Vercauteren <i>et al.</i> , "CD133 (AC133) expression on AML cells and progenitors," <i>Cytotherapy</i> , 3(6):449-459, 2001.
✓	C29	Xu <i>et al.</i> , "One-step analysis and quantification of RNA by RT-PCR: using high-temperature reverse transcription," <i>Focus</i> , 22(1):3-5, 2000.
✓	C30	Yin <i>et al.</i> , "AC133, a novel marker for human hematopoietic stem and progenitor cells," <i>Blood</i> , 90(12):5002-5012, 1997.
T5 ✓	C31	Yu <i>et al.</i> , "AC133-2, a novel isoform of human AC133 stem cell antigen," <i>Journal of Biological Chemistry</i> , 277(23):20711-20716, 2002.

25330684.1

EXAMINER:

Teresa Stuecklein

DATE CONSIDERED:

4/7/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

AUG 20 2004

Atty. Docket No.

UTSC:755US

Serial No.

10/618,102

List of Patents and Publications for Applicant's
INVENTION & TRADEMARKS

Applicant

Edward H. Lin et al.

Filing Date:

July 11, 2003

Group:

1623-1637

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
TS	A3	6,455,678	9/24/02	Yin et al.	530	395	4/23/97

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
TS	B1	WO 97/41224	11/06/97	PCT	—	—	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25443949.1


EXAMINER: Telesio Stuelecia

DATE CONSIDERED:

8/7/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH
CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:755US	Serial No. 10/618,102
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Edward H. Lin <i>et al.</i>	
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>


 AUG 12 2005

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
TS	A4	5,776,154	07/07/98	Taylor <i>et al.</i>	606	167	2/20/97

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25560847.1

 EXAMINER: *Teresa Strielecka* | DATE CONSIDERED: *4/7/06*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.